En Es
Categories

Industry News

Global Lateral Flow Assay Market to Exceed 8 Billion by 2022

By Labmedica International staff writers
08 Sep 2017

Image: The global lateral flow assay market is projected to grow to USD 8.24 billion by 2022 (Photo courtesy of Alere).The global lateral flow assay market is projected to grow at a CAGR of 8.2% from USD 5.55 billion in 2017 to USD 8.24 billion by 2022, driven mainly by the high prevalence of infectious diseases worldwide, rapidly growing geriatric population, growing demand for point-of-care (POC) testing, and rising use of home-based lateral flow assay devices. These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Based on product, the kits & reagents segment held the largest market share in 2016, due to the increasing application of lateral flow kits & reagents for POC testing, growing burden of chronic diseases, and increasing use of lateral flow kits in home care. On the basis of application, the clinical/POC testing segment accounted for the largest share of the market in 2016, led by rise in population levels and prevalence of chronic diseases, growing pressure to reduce healthcare costs, and increasing demand for patient-centric care. Based on end-user, the hospitals and clinics segment accounted for the largest share of the market in 2016, mainly due to technological advancements, increasing adoption of POC testing, innovative technologies and devices, and growing patient inclination toward fast and early diagnosis.

Geographically, North America held the largest market share in 2016, primarily due to the presence of its highly developed healthcare system, rising geriatric population, increasing incidence of chronic diseases, quick adoption of new innovative products, and a large number of lateral flow assay kits manufacturing companies in this region. However, reluctance among doctors and patients to change existing diagnostic procedures, implementation of excise duty by the US government, and stringent & time-consuming regulatory policies are restraining the growth of the lateral flow assay market.

Alere Inc. (Waltham, MA, USA) dominated the global lateral flow assay market in 2016 due to its diversified product portfolio of lateral flow assay kits and readers, as well as innovative contributions to the lateral flow assay market. Over the years, the company has developed innovative lateral flow assay products for various medical applications, such as POC testing products that make workflows more efficient and provide quality test results. The company has a strong manufacturing and distribution network across the globe, which allows it to serve customers across the Americas, Africa, Europe, the Middle East, and Asia-Pacific.



E-mail Print
FaceBook Twitter Google+ Linked in

Alere

Develops rapid point-of-care diagnostics that focus on infectious disease, cardiology, oncology, drugs of abuse, and women's health.
More info

Additional news

12 Jun 2018
AI Software Platform Aims to Synthesize Biomedical Knowledge
nference, which focuses on artificial intelligence (AI)-powered life sciences, is developing an AI software platform to synthesize the exponentially growing biomedical knowledge.
Read More
11 Jun 2018
MEDICA 2018 Launches App Competition for Smart Products
The search for the best health app solutions in the world has begun with the launch of the seventh MEDICA App Competition. The competition is meant for applications for smart phones, smart watches, tablets or AR/VR glasses, but excludes fitness or wellness applications. All submitted applications for the MEDICA App Competition 2018 must have a connection with professional medical technology, and applications from start-ups that are still in the early stage are also invited.
Read More
07 Jun 2018
New AI Algorithm Makes Liver Cancer Surgery Safer
Researchers at the Fraunhofer Institute for Medical Image Computing MEVIS have developed algorithms that analyze patients’ imaging data and calculate surgical risks, making liver cancer surgery safer and easier to plan. Researchers at Fraunhofer have been working on image-processing algorithms for use in medicine since 1998. The method is now widely known among physicians as MEVIS analysis and has become established in practice.
Read More
07 Jun 2018
AI-based Interpretation Tool Receives CE Certification
qXR, an AI-based chest X-ray interpretation tool that detects 15 of the most common chest X-ray abnormalities with an accuracy of more than 90%, has received CE certification. Developed by healthcare AI start-up Qure.ai, qXR has been trained on more than one million chest X-rays and uses a heat map or bounding box to point out abnormalities to the clinician, aiding rapid con?rmation in just milliseconds.
Read More
07 Jun 2018
Global Radiation Detection Market to Reach USD 2 Billion by 2022
The global radiation detection, monitoring, and safety market is expected to grow at a CAGR of 5.7% from USD 1.71 billion in 2017 to USD 2.26 billion by 2022. The market is likely to be driven by rising security threats, increasing prevalence of cancer across the world, growing safety awareness among people working in radiation-prone environments, rising safety concerns following the Fukushima disaster, expanding security budgets of global sporting events, increase in the number of PET/CT scans, growing usage of nuclear medicine and radiation therapy for diagnosis and treatment, and use of drones for radiation monitoring. However, nuclear energy alternatives such as renewable energy, nuclear power phase-out, and shortage of nuclear power workforce, are likely to limit the market growth.
Read More
06 Jun 2018
Siemens Healthineers and ScreenPoint Medical to Develop AI-Based Apps
Siemens Healthineers and ScreenPoint Medical have entered into a partnership to develop artificial intelligence (AI)-based applications for breast imaging. As part of the arrangement, Siemens Healthineers will also acquire a strategic minority stake in ScreenPoint Medical.
Read More
06 Jun 2018
Qure.ai Partners with Teleradiology Solutions for Smarter Diagnoses
Healthcare artificial intelligence (AI) provider, Qure.ai has partnered with Teleradiology Solutions and Telerad Tech to enable smarter and faster diagnoses of X-ray and CT scan data, and reduce costs.
Read More
06 Jun 2018
Algorithms to Enhance Approach for Detecting Tumors
Case Western Reserve University has entered into a collaboration with the Quantum team at Microsoft to use the power of quantum computing for improving patient care. CWRU will use Microsoft’s quantum-inspired algorithms to enhance their approach to detecting cancerous tumors.
Read More
31 May 2018
CerTest Biotec Opens New Facility for Diagnostic Products
CerTest Biotec, a biotechnology company focused on the development and manufacturing of IVD diagnostic products, has opened a new facility in Spain for the research, development and manufacture of molecular diagnostics products.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions